SavedAdd your journal

Journals / Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2015 / Cilt: 26 - Sayı: 3

A Case of Antiphospholipid Syndrome with Poor Prognosis: Improvement with Early Diagnosis and Effective Treatment

Erken Tanı ve Etkin Tedavi ile Düzelen Kötü Prognoz Kriterlerine Sahip Katastrofik Antifosfolipid Sendromu Olgusu

Abdullah ÖZKÖK
Sinan KAZAN
Mehmet ALİUSTAOĞLU
Mehmet Engin TEZCAN
Seydahmet AKIN
Savaş Volkan KİŞİOĞLU
Erman ÖZDEMİR
Pages
263–266
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Parenteral cyclophos- phamide, oral steroid therapy, and anticoagulation was initiated as maintenance therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 40-year-old male patient was admitted with shortness ofbreath and chest pain.
📊
Key Findings & Data:After diagnosis, a total of 6 grams of pulsatilesteroids, intravenous immunoglobulin, plasma exchange, andanticoagulation was administered.
💡
Conclusion & Impact:Parenteral cyclophos- phamide, oral steroid therapy, and anticoagulation was initiated as maintenance therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 40-year-old male patient was admitted with shortness ofbreath and chest pain. Ventilation/perfusion scan showed highrisk for pulmonary embolism, and portal thrombosis was observed with portal magnetic resonance (MR) angiography. Active renal involvement, pancy topenia, and hemoly tic anemiawere also observed. Laboratory tests for lupus anticoagulant,antinuclear antibody, and anti double-stranded DNA werepositive. After other possible diagnoses were excluded, connective tissue disease and possible catastrophic antiphospholipidsyndrome (CAFS) were diagnosed. The patient had all high-riskfactors of CAFS. After diagnosis, a total of 6 grams of pulsatilesteroids, intravenous immunoglobulin, plasma exchange, andanticoagulation was administered. Blood and kidney functionimproved with aggressive treatment. Parenteral cyclophos- phamide, oral steroid therapy, and anticoagulation was initiated as maintenance therapy.

Özet

Kırk yaşında erkek hasta, nefes darlığı ve göğüs ağrısı nedeniile hastaneye başvurması sonrası, kliniğine göre planlanan incelemelerde, ventilasyon perfüzyon sintigrafisi ile yüksek riskle pulmoner emboli, portal sistemde, çekilen MR anjiyografiile tromboz, aktif böbrek tutulumu, pansitopeni ve hemolitikanemi saptandı. Laboratuvar testlerinde lupus antikoagulanı,antinükleer antikor, anti-Ds DNA pozitif saptandı. Hastada diğer muhtemel nedenlerin ekartasyonu sonrası, bağ dokusuhastalığı ve olası katastrofik antifosfolipid sendromu (KAFS)tanısı kondu. Hastada KAFS için yüksek risk faktörleri mev- cuttu. Tanı sonrası, toplam 6 gram pulse steroid, intravenözimmünoglobulin, plazma değişimi ve antikoagülasyon uygu- landı. Agresif tedavi ile hastanın kan tablosu ve böbrek fonk- siyonları düzeldi. Hastaya idame tedavi olarak, parenteral sik- lofosfamid, antikoagülasyon ve oral steroid tedavisi başlandı.

🔖

Cite This Article

ÖZKÖK, A., KAZAN, S., ALİUSTAOĞLU, M., TEZCAN, M. E., AKIN, S., KİŞİOĞLU, S. V., ÖZDEMİR, E. (2022). A Case of Antiphospholipid Syndrome with Poor Prognosis: Improvement with Early Diagnosis and Effective Treatment. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 26 - Sayı: 3, 263–266. https://ajindex.com/articles/571326

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification cri- teria and treatment guidelines. Lupus 2003;12(7):530–4
  2. Bildacı YD, Erkan D. Katastrofik antifosfolipid sendromu: Tanısal zorluklar ve güncellenmiş tanı algoritmaları. RAED Dergisi 2012;4(2):52–8
  3. Cervera R. CAPS Registry. Lupus 2012;21(7):755–7
  4. Erkan D, Espinosa G, Cervera R. Catastrophic antiphos- pholipid syndrome: updated diagnostic algorithms. Au- toimmun Rev 2010;10(2):74–9
  5. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003;15(5):528–34
  6. Asherson RA, Pierangeli S, Cervera R. Microangiopathic antiphospholipid-associated syndromes revisited new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol 2007;34(9):1793–5
  7. Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998;28(1):1–19
  8. Espinosa G, Berman H, Cervera R. Management of refrac- tory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011;10(11):664–8
  9. Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asher- son R; Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphos- pholipid syndrome in the absence and presence of lu- pus. J Rheumatol 2007;34(2):346–52
  10. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez- Puerta JA, Ramos-Casals M, et al. Mortality in the cata- strophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006;54(8):2568–76
  11. Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, et al. Long term outcome of catastrophic an- tiphospholipid syndrome survivors. Ann Rheum Dis 2003;62(6):530–3
  12. Asherson RA, Espinosa G, Menahem S, Yinh J, Bucciarelli S, Bosch X, et al. Relapsing catastrophic antiphospho- lipid syndrome: report of three cases. Semin Arthritis Rheum 2008;37(6):366–72
  13. Katikireddi VS, Kandiah DA. Progression of antiphospho- lipid antibody syndrome to catastrophic antiphospho- lipid antibody syndrome acutely with cessation of anti- thrombotic therapy. Intern Med J 2012;42(5):585–91.